NIH – Alzheimer’s Disease Sequencing Project Functional Genomics Consortium (U01 Clinical Trial Not Allowed)

February 26, 2020 by


This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team-science strategy and apply high-throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimer’s disease and related dementias (AD/ADRD).


This Funding Opportunity Announcement (FOA) is issued as an initiative tied to activities outlined in the National Plan to Address Alzheimer’s Disease 2019 Update (See Strategy 1.B). The National Plan is updated on an annual basis in response to the National Alzheimer’s Project Act (NAPA) Public Law 111-375. The NIA-funded Alzheimer’s Disease Sequencing Project (ADSP) aims at identifying genes and genetic variants associated with risk of and protection against Alzheimer’s disease (AD). The overarching goals of the ADSP are to: (1) identify new genes and variants involved in Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD), (2) identify gene alleles and allelic variants contributing to increased risk for or protection against the disease, (3) provide insight as to why individuals with known risk factors escape developing AD, and (4) identify potential avenues for therapeutic approaches to and prevention of the disease.

Key Dates

Open Date (Earliest Submission Date): June 01, 2020
Letter of Intent Due Date(s): June 1, 2020
Application Due Date(s): July 1, 2020
URL for more information

Filed Under: Funding Opportunities